Mofiyin A. Obadina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mofiyin A. Obadina has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jane A. Little
Adult Sickle Cell Disease Clinic at University of North Carolina‐Chapel Hill Chapel Hill North Carolina USA
2 shared publications Ada Chang
UNC Blood Research Center, University of North Carolina, Chapel Hill, NC, USA
1 shared publication- Ada Chang
UNC Blood Research Center, University of North Carolina , Chapel Hill, NC 27514
1 shared publication Barbara LeVarge
Division of Pulmonary Diseases and Critical Care Medicine, Department of Internal Medicine University of North Carolina Chapel Hill North Carolina USA
1 shared publicationIman Owens
UNC Blood Research Center, University of North Carolina, Chapel Hill, NC, USA
1 shared publication- Iman Owens
UNC Blood Research Center, University of North Carolina , Chapel Hill, NC 27514
1 shared publication
Latest Publications
- Open Access
- 17 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1665-1669
High‐Altitude Hypoxemia in Adults With Sickle Cell Disease ( SCD )
- 17 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1665-1669
Open AccessHigh‐Altitude Hypoxemia in Adults With Sickle Cell Disease ( SCD )
- 26 March 2025
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 7 (6) , 101676
Maternal sleep-associated hypoxemia is common during pregnancy in sickle cell disease: a retrospective review
- 26 March 2025
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 7 (6) , 101676
Maternal sleep-associated hypoxemia is common during pregnancy in sickle cell disease: a retrospective review
- Open Access
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1) , yoaf003
Nocturnal hemoglobin desaturation in chronically transfused adults with sickle cell disease: a retrospective study
High-risk SCD may be managed with chronic red blood cell exchange transfusions. We examined the prevalence of sleep-associated hypoxemia (≥5 minutes at SpO2 ≤88%) or nocturnal Hb desaturation (NHD) in chronically transfused adults with SCD. Of 41 identified participants, 15 (36.6%) had tested positive for NHD at some point prior to enrollment. The median duration of desaturation (SpO2 ≤88%) in those that tested positive was 88.3 minutes (IQR 27.9-226.0 minutes). Participants with and without NHD were compared using non-parametric statistical tests. Compared to participants without NHD, those with NHD had higher absolute reticulocyte counts (P = .018) and white blood counts (P = .05) and tended to be older. They had more anemia (P = .11) and higher lactate dehydrogenase levels (P = .072). Older age at initiation of chronic red blood cell transfusions associated the strongest with a longer duration of NHD (ρ = 0.4253, P = .0067), while prior history of cerebrovascular events associated with a shorter duration of NHD (P = .0315). Our results demonstrate that NHD is common in adults being treated with red blood cell exchange for high-risk SCD and associates with laboratory evidence of increased disease activity. Increased awareness of this complication and appropriate screening may provide an additional simple, low-cost, and physiologically relevant treatment intervention, that is oxygen therapy.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1) , yoaf003
Open AccessNocturnal hemoglobin desaturation in chronically transfused adults with sickle cell disease: a retrospective study
High-risk SCD may be managed with chronic red blood cell exchange transfusions. We examined the prevalence of sleep-associated hypoxemia (≥5 minutes at SpO2 ≤88%) or nocturnal Hb desaturation (NHD) in chronically transfused adults with SCD. Of 41 identified participants, 15 (36.6%) had tested positive for NHD at some point prior to enrollment. The median duration of desaturation (SpO2 ≤88%) in those that tested positive was 88.3 minutes (IQR 27.9-226.0 minutes). Participants with and without NHD were compared using non-parametric statistical tests. Compared to participants without NHD, those with NHD had higher absolute reticulocyte counts (P = .018) and white blood counts (P = .05) and tended to be older. They had more anemia (P = .11) and higher lactate dehydrogenase levels (P = .072). Older age at initiation of chronic red blood cell transfusions associated the strongest with a longer duration of NHD (ρ = 0.4253, P = .0067), while prior history of cerebrovascular events associated with a shorter duration of NHD (P = .0315). Our results demonstrate that NHD is common in adults being treated with red blood cell exchange for high-risk SCD and associates with laboratory evidence of increased disease activity. Increased awareness of this complication and appropriate screening may provide an additional simple, low-cost, and physiologically relevant treatment intervention, that is oxygen therapy.
- Open Access
- 31 May 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (7) , 997-1005
Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations
The underlying mechanisms of disease in sickle cell disease (SCD) contribute to a multifaceted nephropathy, commonly manifested as albuminuria. In severe SCD genotypes (e.g., Hemoglobin SS [HbSS]), albuminuria and CKD are major predictors of mortality in this population. Therefore, the monitoring and management of renal function is an intrinsic part of comprehensive care in SCD. Management of nephropathy in SCD can be accomplished with SCD-directed therapies and/or CKD-directed therapies. In the past 5 years, novel disease-modifying and palliative therapies have been approved in SCD to target aspects of the disease, such as anemia, inflammation, and vasculopathy. Along with conventional hydroxyurea and chronic transfusion, l-glutamine, crizanlizumab, and voxelotor have all been shown to mitigate some adverse effect of SCD, and their effect on nephropathy is being investigated. CKD-directed therapies such as renin–angiotensin–aldosterone system blockers have long been used in SCD nephropathy; however, more complete long-term studies on benefits are needed. Given the effect of renal disease on survival, further assessment of the mechanisms and efficacy of these SCD-directed or CKD-directed therapeutic agents is essential.
- 31 May 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (7) , 997-1005
Open AccessEmerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations
The underlying mechanisms of disease in sickle cell disease (SCD) contribute to a multifaceted nephropathy, commonly manifested as albuminuria. In severe SCD genotypes (e.g., Hemoglobin SS [HbSS]), albuminuria and CKD are major predictors of mortality in this population. Therefore, the monitoring and management of renal function is an intrinsic part of comprehensive care in SCD. Management of nephropathy in SCD can be accomplished with SCD-directed therapies and/or CKD-directed therapies. In the past 5 years, novel disease-modifying and palliative therapies have been approved in SCD to target aspects of the disease, such as anemia, inflammation, and vasculopathy. Along with conventional hydroxyurea and chronic transfusion, l-glutamine, crizanlizumab, and voxelotor have all been shown to mitigate some adverse effect of SCD, and their effect on nephropathy is being investigated. CKD-directed therapies such as renin–angiotensin–aldosterone system blockers have long been used in SCD nephropathy; however, more complete long-term studies on benefits are needed. Given the effect of renal disease on survival, further assessment of the mechanisms and efficacy of these SCD-directed or CKD-directed therapeutic agents is essential.